Current understanding of AD pathophysiology and impact of amyloid beta-targeted treatments on biomarkers and clinical endpoints

Alzheimers Dement. 2022 Aug;18(8):1586. doi: 10.1002/alz.12769. Epub 2022 Aug 10.

Authors

Ronald C Petersen¹, Ana Graf², Maria C Carrillo³, Christopher J Weber³

Affiliations

¹ Mayo Clinic Alzheimer's Disease Research Center, Rochester, Minnesota, USA.
² Novartis Pharma AG, Basel, Switzerland.
³ Alzheimer's Association, Chicago, Illinois, USA.

PMID: 35946224
DOI: 10.1002/alz.12769

No abstract available

MeSH terms

Alzheimer Disease* / drug therapy
Amyloid beta-Peptides*
Biomarkers
Humans
tau Proteins

Substances

Amyloid beta-Peptides
Biomarkers
tau Proteins